Table 1.
Baseline characteristics of the study population of patients without (control) or with inflammatory bowel disease n (%)
|
IBD |
CD |
UC |
|||||||
| Non-IBD control (n = 116436) | IBD cohort (n = 38812) | P value | Non-CD control (n = 37755) | CD cohort (n = 12585) | P value | Non-UC control (n = 78681) | UC cohort (n = 26227) | P value | |
| Age, yr1 | 40.0 ± 16.7 | 40.0 ± 16.7 | - | 30.7 ± 14.6 | 30.7 ± 14.6 | - | 44.4 ± 15.8 | 44.4 ± 15.8 | - |
| < 15 | 3639 (3.1) | 1213(3.1) | 2562 (6.8) | 854 (6.8) | 1077 (1.4) | 359 (1.4) | |||
| 15-39 | 56679 (48.7) | 18893 (48.7) | 26577 (70.4) | 8859 (70.4) | 30102 (38.3) | 10034 (38.3) | |||
| ≥ 40 | 56118 (48.2) | 18706 (48.2) | 8616 (22.8) | 2872 (22.8) | 47502 (60.4) | 15834 (60.4) | |||
| Male gender | 71040 (61.0) | 23680 (61.0) | - | 26451 (70.1) | 8817 (70.1) | - | 44589 (56.7) | 14863 (56.7) | - |
| Rural residence | 62045 (53.3) | 19312 (49.8) | < 0.001 | 20043 (53.1) | 6163 (49.0) | < 0.001 | 42002 (53.4) | 13149 (50.1) | < 0.001 |
| Lowest income 20%2 | 33008 (28.4) | 9316 (24.0) | < 0.001 | 10705 (28.4) | 3229 (25.7) | < 0.001 | 22303 (28.6) | 6087 (23.2) | < 0.001 |
| DM | 5786 (5.0) | 1612 (4.2) | < 0.001 | 845 (2.3) | 280 (2.2) | 0.931 | 4941 (6.3) | 1332 (5.1) | < 0.001 |
| Hypertension | 14958 (12.9) | 4494 (11.6) | < 0.001 | 2294 (6.1) | 665 (5.3) | 0.001 | 12664 (16.1) | 3829 (14.6) | < 0.001 |
| Dyslipidemia | 8620 (7.4) | 2718 (7.0) | 0.009 | 1358 (3.6) | 376 (3.0) | 0.001 | 7262 (9.2) | 2342 (8.9) | 0.145 |
| Congestive heart failure | 781 (0.7) | 356 (0.9) | < 0.001 | 119 (0.3) | 85 (0.7) | < 0.001 | 662 (0.8) | 271 (1.0) | 0.004 |
| Ischemic heart disease | 4028 (3.5) | 1747 (4.5) | < 0.001 | 616 (1.6) | 381 (3.0) | < 0.001 | 3412 (4.3) | 1366 (5.2) | < 0.001 |
| Gout and/or hyperuricemia | 1552 (1.3) | 650 (1.7) | < 0.001 | 320 (0.9) | 211 (1.7) | < 0.001 | 1232 (1.6) | 439 (1.7) | < 0.001 |
| Medications for IBD | |||||||||
| 5-ASA | 121 (0.1) | 36288 (93.5) | < 0.001 | 32 (0.1) | 11233 (89.3) | < 0.001 | 89 (0.1) | 25055 (95.5) | < 0.001 |
| Corticosteroids | 0 (0.0) | 22284 (57.4) | < 0.001 | 0 (0.0) | 7382 (58.7) | < 0.001 | 0 (0.0) | 14902 (56.8) | < 0.001 |
| Immunomodulators | 0 (0.0) | 10356 (26.7) | < 0.001 | 0 (0.0) | 6982 (55.5) | < 0.001 | 0 (0.0) | 3374 (12.9) | < 0.001 |
| Anti-TNF-α | 0 (0.0) | 2103 (5.4) | < 0.001 | 0 (0.0) | 1659 (13.2) | < 0.001 | 0 (0.0) | 444 (1.7) | < 0.001 |
| Follow-up period, yr1 | 4.9 ± 1.3 | 4.9 ± 1.3 | 0.337 | 4.9 ± 1.3 | 4.9 ± 1.3 | 0.004 | 4.9 ± 1.3 | 4.9 ± 1.3 | 0.418 |
1
Mean ± SD;
2
Defined as patients whose income was in the bottom 20%. ASA: Aminosalicylic acid; CD: Crohn’s disease; DM: Diabetic mellitus; IBD: Inflammatory bowel disease; TNF: Tumor necrosis factor; UC: Ulcerative colitis.